Contacts
Groups
- Researcher, The Hannan Group - Cancer Therapeutics
Projects
- Researcher, RNA polymerase I inhibitors as therapeutics for cancer: analysis of p53 -dependent and – independent cell cycle checkpoints
- Researcher, RNA polymerase I inhibitors as therapeutics for cancer: Testing combination therapies for haematologic malignancies
- Supervisor, Click chemistry enables evaluation of the molecular mechanism of the 2nd generation RNA polymerase I inhibitor, PMR-116
- Supervisor, Regulation of chromatin remodeling of the rRNA genes in mouse embryonic stem cells
Devlin, JR, Hannan, KM, Hein, N, Cullinane, C, Kusnadi, E, Ng, PY, George, AJ, Shortt, J, Bywater, MJ, Poortinga, G, Sanij, E, Kang, J, Drygin, D, O'Brien, S, Johnstone, RW, McArthur, GA, Hannan RD and Pearson, RB (2016) Combination therapy targeting ribosome biogenesis and mRNA translation synergistically extends survival in MYC-driven lymphoma. Cancer Discovery 6(1):59-70
Quin, J, Chan, KT, Devlin, JR, Cameron, DP, Diesch, J, Cullinane, C, Ahern, J, Khot, A, Hein, N, George, AJ, Hannan, KM, Poortinga, G, Sheppard, KE, Khanna, KK, Johnstone, RW, Drygin, D, McArthur, GA, Pearson, RB, Sanij E and Hannan, RD (2016) Inhibition of RNA Polymerase transcription initiation activates non-canonical ATM/ATR signaling. Oncotarget. 2016 Jul 6. doi: 10.18632/oncotarget.10452. [Epub ahead of print]
